Isturisa FDA Approval History
Last updated by Judith Stewart, BPharm on March 31, 2020.
FDA Approved: Yes (First approved March 6, 2020)
Brand name: Isturisa
Generic name: osilodrostat
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome
Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease.
Development timeline for Isturisa
| Date | Article |
|---|---|
| Mar 8, 2020 | Approval FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
